Symdeko
Total Payments
$15,850
Transactions
6
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $15,850 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15,850 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis | VERTEX PHARMACEUTICALS INCORPORATED | $12,850 | 0 |
| Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis | Vertex Pharmaceuticals Incorporated | $3,000 | 0 |
Top Doctors Receiving Payments for Symdeko
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Kansas City, MO | $15,850 | 6 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $15,850
- Total Doctors 0
- Transactions 6
About Symdeko
Symdeko is a drug associated with $15,850 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is VERTEX PHARMACEUTICALS INCORPORATED.
Payment data is available from 2018 to 2018. In 2018, $15,850 was paid across 6 transactions to 0 doctors.
The most common payment nature for Symdeko is "Unspecified" ($15,850, 100.0% of total).
Symdeko is associated with 2 research studies, including "Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis" ($12,850).